Tag Archives: BIO International Convention

Why We Do This Work

rachel-king

In her keynote remarks delivered yesterday at the 2014 BIO International Convention, Rachel King, president & CEO of GlycoMimetics and chairperson of the board of the Biotechnology Industry Organization (BIO), talked about why entrepreneurs pursue opportunities in biotechnology and what sustains these industry leaders through the rollercoaster of raising money, clinical trials, road shows and all the ups and downs of bringing medical innovations from the lab to the bedside. “Working in biotechnology today, we Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Seeing is Believing

brain-scan

PET and MRI imaging helps companies to make go/no go decisions earlier Attrition or failure of new drug programs is a major source of concern, with failure rates ranging from 75 percent in anti-infectives to 92 percent in CNS according to DiMasi’s 2010 study (Clin. Pharmacol. Ther. 87, 272-277). Molecular imaging – both Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) can help improve these dismal statistics. Given the immense costs involved in the Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

A Better Way to Make Unnatural Amino Acids Discovered by Yu

Make Unnatural Amino Acids

Certain amino acids that are not found in nature are highly sought after by pharmaceutical manufacturers. These “unnatural” amino acids have traditionally been very difficult to synthesize, so a new and improved technique for doing so is attracting a lot of attention. Amino acids are among the most basic components of living things. Long chains of them, translated from DNA, fold up to become proteins, some smaller groupings of amino acids form hormones, and a Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

New Target for Alzheimer’s Disease

shutterstock_27160801

Biotechnologists have developed a drug candidate that blocks production of diseasecausing neurotoxins in mouse models Reducing the concentration of cathepsin B using an enzyme inhibitor prevents the creation of the neurotoxic peptide, pyroglutamate-AB (pGlu-AB), which has been linked to the development of Alzheimer’s disease (AD). The candidate inhibitor drug, a cysteine protease inhibitor named E64d, was developed by scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Making the Case for Personalized Medicine

Personalized-Medicine

Personalized medicine is the customization of healthcare. Already, a suite of molecular approaches is being used to tailor certain medical decisions, practice and products to the individual patient. For example, melanoma, leukemia and metastatic lung, breast and brain cancers can be routinely “molecularly diagnosed” and treated with medicines that target the specific genetic mutations. These represent a remarkable improvement over trial-and-error medicine. Other diagnostic tests use the patient’s DNA sequence to determine drug-metabolizing capabilities. This Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,